The study examines the prevalence of lung cancer screening (LCS) in the US in 2022, comparing it under 2013 and 2021 USPSTF eligibility criteria. The 2013 criteria recommended LCS for individuals aged 55-80 with a 30-pack-year smoking history, while the 2021 criteria expanded eligibility to those aged 50-79 with a 20-pack-year history. In 2022, the weighted LCS-eligible population increased by 65.9% under the 2021 criteria, with 16.4% and 19.6% prevalence rates using 2021 and 2013 criteria, respectively. The number of newly eligible individuals aged 50-54 increased by 6.1%, and those with a 20-29 pack-year history had a 13.1% screening rate. Expanded criteria led to the largest relative increases in eligibility among Asian (88%), Black (109%), and Hispanic (86%) populations, as well as females. LCS prevalence varied by state, with higher rates in the Northeast and Mid-Atlantic regions. No significant differences were found between 2021 and 2013 criteria by state. Despite the expanded eligibility, LCS prevalence remained low, indicating a need for further efforts to increase screening rates. The study highlights the importance of updated eligibility criteria in reducing disparities but notes that screening rates remain low, emphasizing the need for public health initiatives to improve LCS uptake.The study examines the prevalence of lung cancer screening (LCS) in the US in 2022, comparing it under 2013 and 2021 USPSTF eligibility criteria. The 2013 criteria recommended LCS for individuals aged 55-80 with a 30-pack-year smoking history, while the 2021 criteria expanded eligibility to those aged 50-79 with a 20-pack-year history. In 2022, the weighted LCS-eligible population increased by 65.9% under the 2021 criteria, with 16.4% and 19.6% prevalence rates using 2021 and 2013 criteria, respectively. The number of newly eligible individuals aged 50-54 increased by 6.1%, and those with a 20-29 pack-year history had a 13.1% screening rate. Expanded criteria led to the largest relative increases in eligibility among Asian (88%), Black (109%), and Hispanic (86%) populations, as well as females. LCS prevalence varied by state, with higher rates in the Northeast and Mid-Atlantic regions. No significant differences were found between 2021 and 2013 criteria by state. Despite the expanded eligibility, LCS prevalence remained low, indicating a need for further efforts to increase screening rates. The study highlights the importance of updated eligibility criteria in reducing disparities but notes that screening rates remain low, emphasizing the need for public health initiatives to improve LCS uptake.